[1] 王瀚,丛文铭.双表型肝细胞癌新亚型的临床病理学研究进展[J].中国肿瘤临床,2017,44(12):616-619.
[2] 姚瑶,范钦和,李红霞,等.双表型肝细胞癌的临床病理分析[J].局解手术学杂志,2023,32(1):79-83.
[3] Lee J I,Lee J W,Kim J M,et al.Prognosis of hepatocellular carcinoma expressing cytokeratin 19:comparison with other liver cancers[J].World J Gastroenterol,2012,18(34):4751-4757.
[4] Komuta M,Yeh M M.A review on the update of combined hepatocellular cholangiocarcinoma[J].Semin Liver Dis,2020,40(2):124-130.
[5] Lu X Y, Xi T, Lau W Y,et al.Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J].Ann Surg Oncol, 2011, 18(8):2210-2217.
[6] Cong W M,Bu H,Chen J,et al.Practice guidelines for the pathological diagnosis of primary liver cancer:2015 update[J].World J Gastroenterol,2016,22(42):9279-9287.
[7] Cong W M,Wu M C.New insights into molecular diagnostic pathology of primary liver cancer:Advances and challenges[J].Cancer Lett,2015,368(1):14-19.
[8] 丛文铭. 双表型肝癌[M]//肝胆肿瘤外科病理学.北京:人民卫生出版社,2015:318-319.
[9] 邹柯涵,徐敏,罗书笛,等.CK,Ki67,Gly-3及P53在肝细胞癌组织中的表达[J].湖南中医药大学学报,2017,37(3):326-328.
[10] 刘冰,杨帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169-170.
[11] 符媛媛,李可帅,张小燕.肝细胞癌的免疫组化、分子检测及MRI诊断评价[J].实用癌症杂志,2022,37(10):1670-1673.
[12] 史连国,方庆全,陈宏.双表型肝细胞癌的临床病理特征[J].中国实用医刊,2021,48(10):13-16. |
